Search results
Moderna wins FDA approval for RSV vaccine
BioPharma Dive via Yahoo Finance· 6 days agoThe OK for mResvia adds another option for preventing RSV-related disease in older adults, one year after the agency cleared shots from GSK and Pfizer.
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks via Yahoo Finance· 2 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the...
Moderna just got FDA approval for its RSV vaccine — only its second product on the market
Quartz· 5 days agoThe Food and Drug Administration on Friday approved Moderna’s mRNA-based respiratory syncytial virus...
Unpacking Averages: Growth of AL/ML in Medicine as Evidenced by Clinical Trials
The National Law Review· 1 day agoMost people have seen the growth in artificial intelligence/ machine learning (AI/ML)-based medical...
FDA approves Moderna’s mRNA RSV vaccine for older adults
KOMU Columbia· 4 days agoThe shot, made by Moderna and sold under the name of mResvia, could be another tool in the country’s...
FDA urged to relax decades-old tissue donation restrictions for gay and bisexual men
San Jose Mercury News· 6 days agoAdvocates, lawmakers, and groups focused on removing barriers to cornea donations, in particular,...
FDA approves Moderna's RSV vaccine for seniors, the company's second-ever product
CNBC· 5 days agoThe Food and Drug Administration on Friday approved Moderna's vaccine for respiratory syncytial ...
Axios Vitals
Axios· 2 days agoFDA vaccine advisers will consider whether updated COVID-19 shots made available this fall should target the JN.1 variant, which until recently had been the most dominant ...
Moderna wins second product approval with RSV vaccine
Market Watch· 5 days agoModerna Inc.’s respiratory syncytial virus vaccine for older adults received U.S. regulatory...
Moderna (MRNA) Secures FDA Nod for mRNA-Based RSV Vaccine
Zacks· 3 days agoThe RSV vaccine is Moderna???s (MRNA) second FDA-approved product. Once the vaccine secures the CDC's recommendation, it will be launched in the 2024-2025 respiratory virus season.
